EU/3/15/1448

About

On 12 February 2015, orphan designation (EU/3/15/1448) was granted by the European Commission to Voisin Consulting S.A.R.L., France, for 505 amino acid protein, corresponding to amino acids 2-506 of the wild type human histidyl-tRNA synthetase for the treatment of facioscapulohumeral muscular dystrophy.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in January 2020 on request of the Sponsor.

Key facts

Active substance
505 amino acid protein, corresponding to amino acids 2-506 of the wild type human histidyl-tRNA synthetase
Disease / condition
treatment of facioscapulohumeral muscular dystrophy
Date of first decision
12/02/2015
Outcome
Withdrawn
EU designation number
EU/3/15/1448

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Voisin Consulting S.A.R.L.
64 Avenue Pierre Grenier
92100 Boulogne-Billancourt
France
Tel. +33 1413 18300
E-mail: orphan@voisinconsulting.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating